Next-Generation Biomarkers and AI-Enhanced Digital Pathology Alliance: Revolutionizing Therapeutic Strategies and Prognostic Assessment in Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 20 August 2026 | Viewed by 1200
Special Issue Editor
Interests: colorectal cancer; biomarkers; minimal invasive therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The management of colorectal cancer is undergoing a paradigm shift, propelled by the emergence of next-generation biomarkers. Moving beyond static, single-analyte tests, this new era is defined by dynamic, multi-modal, and technology-driven tools—from liquid biopsies and multi-omic signatures to AI-enhanced digital pathology. These innovations are fundamentally revolutionizing clinical practice, enabling ultra-sensitive detection of minimal residual disease, real-time monitoring of therapeutic response, and the precise tailoring of treatment strategies to an individual’s unique tumor biology. This Special Issue, titled “Next-Generation Biomarkers and AI-Enhanced Digital Pathology Alliance: Revolutionizing Therapeutic Strategies and Prognostic Assessment in Colorectal Cancer”, seeks to capture this transformative momentum. We aim to compile cutting-edge research and reviews that illuminate the discovery, validation, and integration of these advanced biomarkers. Our goal is to provide a comprehensive overview of how these tools are refining prognostication, personalizing therapeutic interventions, and ultimately paving the way toward more adaptive and effective patient care.
Dr. Τaxiarchis Κonstantinos Νikolouzakis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liquid biopsy
- precision oncology
- predictive prognostication
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
